Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: A network meta-analysis

International Journal of COPD

Volumn 7, Issue , 2012, Pages 415-420

  Cope, Shannon ^a   Kraemer, Matthias ^b   Zhang, Jie ^b   Capkun Niggli, Gorana ^b   Jansen, Jeroen P ^a  

^a MAPI Consultancy   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disorder; COPD; Indacaterol; Network meta analysis

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; INDACATEROL; PLACEBO; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; BUDESONIDE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; FORMOTEROL; GLUCOCORTICOID; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; TRANSITIONAL DYSPNEA INDEX; DRUG COMBINATION; DRUG EFFECT; METHODOLOGY;

ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSPNEA; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INDANS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871675192     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S31526     Document Type: Article

References (34)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2010. Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed June 1, 2011.
2. Katz PM, Pegoraro V. L'utilizzo dei corticosteroidi nei pazienti con la broncopneumopatia cronica ostruttiva: aspetti epidemiologici ed economici. Farmeconomia e percorsi terapeutici. 2009;10(4):139-148.
3. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425-1429.
4. Jochmann A, Neubauer F, Miedinger D, et al. General practitioners' adherence to the COPD GOLD guidelines: baseline data from the Swiss COPD cohort. Swiss Med Wkly. April 21, 2010. [Epub ahead of print.]
5. Joo MJ, Lee TA, Bartle B, van de Graaff WB, Weiss KB. Patterns of healthcare utilization by COPD severity: a pilot study. Lung. 2008; 186(5):307-312.
6. Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease - a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011;6:329-344.
7. US Drug and Food Administration. News release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261649.htm. Accessed May 3, 2012.
8. Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged $ 40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011;33(12):1974-1984.
9. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
10. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10(11):1-9.
11. Barnes N, Qiu Y, Pavord I, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173(7):736-743.
12. Calverley P, Pauwels R, Vestbo Jr, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
13. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
14. Calverley P, Anderson J, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
15. Hanania N, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 mug)/salmeterol (50 mug) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3): 834-843.
16. Mahler D, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084-1091.
17. Zheng J, Yang L, Wu Y, et al. The efficacy and safety of combination salmeterol (50 mug)/fluticasone propionate (500 mug) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest. 2007; 132(6):1756-1763.
18. Rennard SI, Tashkin D, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549-565.
19. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 68(14):1975-2000.
20. Jack D, Bleasdale P, Berhane I, Higgins M. Full Clinical Study Report for study number CQAB149B2334: a 52-week treatment, multi-center, randomized, doubleblind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 and 600 μg OD) in patients with chronic obstructive pulmonary disease, using formoterol (12 μg BID) as an active control. Data on file: 2008.
21. Prasad N, Piggott S, Higgins M, Yu T. Full Clinical Study Report for study number CQAB149B2346: a 12-week treatment, multi-center, randomized, doubleblind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol (150 μg OD) in patients with chronic obstructive pulmonary disease. Data on file: 2008.
22. Iqbal A, Lean H, Lawrence D, Higgins M. Full Clinical Study Report for study number CQAB149B2335S: a 26-week treatment, multi-center, randomized, doubleblind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 and 600 μg OD) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 μg BID) and open label tiotropium (18 μg OD) as active controls. Data on file: 2008.
23. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
24. Luthra A, Kramer B, Swales J, Henley M, Lassen C. Full Clinical Study Report for study number CQAB149B2336: a 26-week treatment, multi-center, randomized, doubleblind, double dummy, placebo controlled, parallel-group study to assess the efficacy and safety of indacaterol (150 μg OD) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg BID) as an active control. Data on file: 2009.
25. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
26. Hosoe M, Okino N, Maruyama Y, et al. Full Clinical Study Report for study number CQAB149B1302: a 12-week treatment, multi-center, randomized, doubleblind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (150 and 300 ìg OD) in patients with chronic obstructive pulmonary disease (COPD). Data on file: 2010.
27. Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease (COPD) patients from six Asian areas including Japan: A 12-week, placebo controlled study. Respirology. 2012;17(2):379-389.
28. Firth R, Henley M, Kramer B, Lassen C, Yang W, Owen R. Full Clinical Study Report for study number QAB149B2333: a phase III, 26-week multi-center randomized doubleblind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (150 and 300 ìg OD) in patients with chronic obstructive pulmonary disease. Data on file: 2010.
29. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897-900.
30. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-3124.
31. Jansen J, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11(5):966-964.
32. Dempster AP. The direct use of likelihood for significance testing. Stat Comput. 1997;7(4):247-252.
33. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14): 1861-1881.
34. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325-337.